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ABSTRACT
Objective: Dabigatran was recently approved for
anticoagulation in patients with atrial fibrillation (AF);
data regarding real-world use, comparative
effectiveness and safety are sparse.
Design: Pharmacoepidemiological cohort study.
Methods/settings: From nationwide registers, we
identified patients with an in-hospital or outpatient-
clinic AF diagnosis who claimed a prescription of
dabigatran 110 or 150 mg, or vitamin K antagonist
(VKA), between 22 August and 31 December 2011.
HRs of thromboembolic events (ischaemic stroke,
transitory ischaemic attack and peripheral artery
embolism) and bleedings were estimated using Cox
regression analyses in all patients and stratified by
previous VKA use.
Results: Overall, 1612 (3.1%) and 1114 (2.1%)
patients claimed a prescription of dabigatran 110 and
150 mg, and 49640 (94.8%) of VKA. Patients treated
with dabigatran 150 mg were younger with less
comorbidity than those treated with dabigatran 110 mg
and VKA, as were VKA naïve patients compared with
previous VKA users. Recommendations set by the
European Medicine Agency (EMA) for dabigatran were
met in 90.3% and 55.5% of patients treated with 110
and 150 mg. Patients treated with 150 mg dabigatran,
who did not fulfil the recommendations by EMA, were
>80 years, patients with liver or kidney disease,
patients with previous bleeding. Compared with VKA,
the thromboembolic risk associated with dabigatran
110 and 150 mg was HR 3.52 (1.40 to 8.84) and
5.79 (1.81 to 18.56) in previous VKA users, and
HR 0.95(0.47 to 1.91) and 1.14(0.60 to 2.16) in VKA
naïve patients. Bleeding risk was increased in previous
VKA users receiving dabigatran 110 mg, but not in
patients with 150 mg dabigatran, nor in the VKA naïve
users.
Conclusions: Deviations from the recommended use
of dabigatran were frequent among patients treated
with 150 mg. With cautious interpretation, dabigatran
use in VKA naïve patients seems safe. Increased risk of
thromboembolism and bleeding with dabigatran among
previous VKA users was unexpected and may reflect
patient selection and ‘drug switching’ practices.
INTRODUCTION
Stroke is a serious complication of atrial ﬁb-
rillation (AF), and prevention with antith-
rombotic medication has high priority.1 2
Until recently, vitamin K antagonists (VKA)
have been the drug of ﬁrst choice in high-
risk patients with AF,3 but food and drug
interactions and the need for frequent
ARTICLE SUMMARY
Article focus
▪ To describe dabigatran use in atrial fibrillation
(AF) patients and compare it with vitamin K
antagonist (VKA) use.
▪ To describe if dabigatran is prescribed according
to the recommendations set by authorities.
▪ To estimate initial risk of thrombosis and bleed-
ings related to dabigatran and VKA use among
all patients, and stratified by previous use of
VKA.
Key messages
▪ Dabigatran was prescribed in approximately 5%
of AF patients with oral anticoagulation during
the initial 4 months after approval.
▪ Recommendations set by the European Medicine
Agency for dabigatran were met in 90.3% and
55.5% of patients treated with 110 and 150 mg,
respectively.
▪ Compared with VKA, the thromboembolic risk
associated with dabigatran 110 and 150 mg was
higher in previous VKA users, but comparable in
VKA naive patients. Bleeding risk was increased
in previous VKA users (D110 mg). Increased risk
of thromboembolism and bleeding with dabiga-
tran among previous VKA users may reflect
patient selection and ‘drug switching’ practices.
Strengths and limitations of this study
▪ The main strength is the nationwide complete
dataset of unselected AF patients and the use of
validated pharmacoepidemiological methods.
▪ The main limitation is the short follow-up time.
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monitoring within a narrow therapeutic range makes
VKA unattractive to many patients.4
The novel oral anticoagulant dabigatran etexilate has
been compared with VKA in patients with non-valvular
AF in a large phase 3 randomised trial; it has been
shown to be non-inferior to VKA with a comparable or
lower risk of strokes, and with a more favourable side-
effect proﬁle concerning serious bleedings.4 Dabigatran
has fewer interactions with food and drugs than VKA
and does not need monitoring of its anticoagulant
effect.5 Moreover, dabigatran 150 mg twice daily was
superior to VKA in preventing stroke, with an additional
overall reduction of cardiovascular mortality, and
without increasing the risk of major bleeding.4 In
patients with a clear indication for oral anticoagulation
and without contraindications for therapy, the 2012
focused update of the European Society of Cardiology
AF guidelines recommends one of the novel anticoagu-
lants (dabigatran, rivaroxaban or apixaban) as a ﬁrst-line
choice of anticoagulation.2 6 7
Dabigatran was the ﬁrst drug to be approved by the
authorities for patients with non-valvular AF; however,
the approval was followed by several concerns including
case reports of serious bleedings8 9 as well as concerns
about poor adherence to therapy.10 Consequently, the
Food and Drug Administration (FDA) in the USA, and
European Medicine Agency (EMA) brought a safety
announcement of serious bleedings.11 12 EMA has
approved the use of dabigatran in AF patients if one of
the following risk factors are present: previous stroke,
transient ischaemic attack, age ≥75 years, left-ventricular
ejection fraction <40% or age ≥65 years with one of the
following: diabetes, coronary heart disease or hyperten-
sion. A dose of 150 mg twice daily is recommended
unless the patients are ≥80 years, or with an increased
risk of bleeding where a dose of 110 mg twice daily is
preferred/should be considered.2 The 2012 European
Society of Cardiology guidelines on AF management
state that dabigatran 150 mg twice daily is the default
dose, with the 110 mg twice daily dose being recom-
mended in those aged ≥80 years, with high bleeding
risk (HAS-BLED ≥3) and concomitant interacting drugs
(eg, verapamil).2
Until now, only preliminary real-life postapproval data
have reported on the use of dabigatran.13–15 The
purpose of this nationwide cohort study was to describe
initial postapproval use, comparative effectiveness and
safety of treatment with dabigatran 110 and 150 mg
twice daily among patients with AF, compared with those
with VKA, during the initial 4 months after approval.
METHODS
Data sources
Nationwide administrative registers were linked on an
individual level. For this study, we used: (1) The Danish
National Patient Register, which holds information on
all admissions to Danish hospitals since 1978 with one
primary and, if appropriate, one or more secondary
diagnoses coded according to the International
Classiﬁcation of Diseases (ICD) 8 and 10. (2) The
National Prescription Register holds information on all
prescriptions dispensed in Danish pharmacies since
1995 (coded according to the Anatomical Therapeutic
Chemical (ATC) classiﬁcation system), including infor-
mation on the date of dispensation, strength and
number of tablets dispensed. All pharmacies are
required by Danish legislation to provide information
that ensures complete and accurate registration.16 17
(3) The Civil Register holds information of vital status of
all citizens.
Study population
We identiﬁed all Danish residents registered with a diag-
nosis of AF (ICD-10 code I48) between 1 January 1995
and 31 December 2011 by the Danish National Patient
Register (see online supplementary ﬁgure S1). All AF
patients admitted to the hospital with AF, managed for
AF in an outpatient clinic/ambulatory or seen at an
emergency department contact for AF were eligible
for the study.
Warfarin and dabigatran therapy
Patients with a prescription claim of VKA (ATC
B01AA03) or dabigatran (ATC B01AE07) between 22
August and 31 December 2011 were included.
According to their ﬁrst prescription claim in this period,
patients were stratiﬁed in three groups: VKA, dabigatran
110 mg twice daily and dabigatran 150 mg twice daily.
Prescription claims of VKA from 0 to 180 days prior to
baseline stratiﬁcation were registered and classiﬁed as
previous VKA therapy. Furthermore, patients were strati-
ﬁed according to previous use of VKA, since risk of
bleeding can be higher in VKA naïve patients than in
previous VKA users.18 19 Use of VKA and dabigatran 110
and 150 mg was included as dichotomous variables since
the study period was short.
Comobidities and concomitant medical therapy
Comorbidities of congestive heart failure, hypertension,
diabetes mellitus, thromboembolism (ischaemic stroke,
transitory ischaemic attack and peripheral artery embol-
ism), vascular disease (myocardial infarction, peripheral
artery disease and aortic plaque) and previous bleeding
within 180 days prior to index (22 August 2011) were
determined, as performed in previous studies.20 21
Concomitant medical treatment with digoxin, amiodar-
one, Class 1C antiarrythmics, sotalol, β-blockers, non-
dihydropyridine calcium channel blockers, non-steroidal
anti-inﬂammatory drugs and aspirin was assessed.
Criteria for comorbidities, ICD-8 and ICD-10 diagnoses
and ATC codes used in the analyses are listed in the
online supplementary material, table 1, and have been
used in similar analyses previously.18 20 CHADS2 (con-
gestive heart failure, hypertension, age ≥75 years, dia-
betes mellitus, stroke/transient ischaemic attack),
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CHA2DS2–VASc (ie, CHADS2 and adding vascular
disease, age 65–75 and female sex) and HAS-BLED
(hypertension, abnormal renal/liver function, stroke,
bleeding history or predisposition, labile international
normalised ratio(left out due to lack of information, as
performed in previous studies), elderly (>65 years),
drugs/alcohol concomitantly) scores were calculated.
Identiﬁcation and validation of these scores in similar
cohorts have been described previously.18 21 22
Prescription patterns
Description of the patients prescribed dabigatran 110
and 150 mg twice daily according to recommendations
Table 1 Baseline characteristics
Treatment group, N (%) Warfarin 2.5 mg Dabigatran 110 mg Dabigatran 150 mg p Value
Characteristics
Number of patients 49640 1612 1114
Age, mean (SD) (years) 73.5 (±10.0) 79.6 (±8.3) 67.9 (±8.15)
Age 65–74 years 16800 (33.8) 278 (17.3) 594 (53.3) <0.001
Age ≥75 years 24487 (49.3) 1245 (77.2) 225 (20.2) <0.001
Female 19380 (39.0) 850 (52.7) 409 (36.7) <0.001
Male 30280 (61.0) 762 (47.3) 705 (63.3) <0.001
Comorbidity
Heart failure 8623 (17.4) 286 (17.7) 84 (7.5) <0.001
Hypertension 27838 (56.1) 834 (51.7) 501 (44.9) <0.001
Diabetes mellitus 8276 (16.7) 241 (15.0) 153 (13.7) 0.007
Previous thromboembolism 3605 (7.3) 136 (8.4) 66 (5.9) 0.04
Vascular disease 6928 (14.0) 265 (16.4) 113 (10.1) <0.001
Alcohol 1723 (3.5) 61 (3.8) 50 (4.5) 0.15
Liver 690 (1.4) 31 (1.9) 17 (1.5) 0.19
Kidney disease 3341 (6.7) 96 (6.0) 36 (3.2) <0.001
Previous bleeding 5171 (10.4) 209 (13.0) 78 (7.0) <0.001
Previous VKA use* 45403 (91.5) 782 (48.5) 349 (31.3) <0.001
No previous VKA use 4237 (8.5) 830 (51.5) 765 (68.7) <0.001
Concomitant therapy
Digoxin 17047 (34.3) 488 (30.3) 207 (18.6) <0.001
Amiodarone 2310 (4.7) 56 (3.5) 36 (3.2) 0.008
Class 1C AA† 979 (2.0) 19 (1.2) 31 (2.8) 0.01
Sotalol 967 (2.0) 27 (1.7) 26 (2.3) 0.47
β-Blockers 31133 (62.7) 808 (50.1) 554 (49.7) <0.001
Non-dihydropyridine CCBs‡ 4215 (8.5) 163 (10.1) 56 (5.0) <0.001
NSAIDs 7567 (15.2) 298 (18.5) 236 (21.2) <0.001
Aspirin 14853 (29.9) 658 (40.8) 435 (39.1) <0.001
CHADS2§
Low (score 0) 8761 (17.7) 141 (8.8) 421 (37.8) <0.001
Intermediate (score 1) 17078 (34.4) 567 (35.2) 407 (36.5) <0.001
High (score 2–6) 23801 (48.0) 904 (56.0) 286 (25.7) <0.001
Mean score (SD) 1.5 (±1.1) 1.8 (±1.1) 1.0 (±1.0) <0.001
CHA2DS2-VASc¶
Low (score 0) 2226 (4.5) 24 (1.5) 99 (8.9) <0.001
Intermediate (score 1) 6405 (12.9) 82 (5.4) 262 (23.5) <0.001
High (score 2–6) 41009 (82.6) 1506 (93.4) 753 (67.6) <0.001
Mean score (SD) 2.9 (±1.5) 3.4 (±1.4) 2.2 (±1.3) <0.001
HAS-BLED**
Low (score 0) 15033 (30.3) 344 (21.4) 404 (36.3) <0.001
Intermediate (score 1) 18569 (37.4) 626 (38.8) 418 (37.5) <0.001
High (score 2–6) 16038 (32.3) 642 (39.8) 292 (26.2) <0.001
Mean score (SD) 2.1 (±1.0) 2.3 (±1.0) 1.86 (±1.0) <0.001
*Previous VKA use: prescription claims of warfarin from 0 to 180 days prior to baseline stratification.
†Class 1C AA:drug coded as ATC ‘C01B’.
‡Non-dihydropyridine CCBs: drugs coded as ‘C08DA’.
§CHADS2: congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischaemic attack.
¶CHA2DS2–VASc: CHADS2, adding vascular disease, age 65–75 and female sex.
**HAS-BLED: hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalised ratio(left out
due to lack of information, as carried out previously), elderly (>65 years), drugs/alcohol concomitantly.
NSAIDs, non-steroidal anti-inflammatory drugs; VKA, vitamin K antagonist.
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by EMA is presented, as are the baseline differences
between previous VKA users and VKA naïve patients.2 11
Endpoints: thromboembolism and bleeding
The following two endpoints were assessed: (1) thrombo-
embolism was deﬁned as an admission with a thrombo-
embolic diagnosis (including ischaemic stroke, transitory
ischaemic attack and peripheral artery embolism). (2)
Bleeding was deﬁned as an admission with a bleeding diag-
nosis (including cerebral bleedings, bleedings from the
respiratory tract, gastrointestinal bleedings and bleedings
from the urinary tract). ICD-10 codes used to deﬁne the
endpoints are listed in online supplementary table S1.
Statistical analyses
Baseline variables for patients on warfarin, dabigatran
110 or 150 mg are presented, referring to the patients’
ﬁrst exposure group, as are the differences in baseline
characteristics in previous VKA users and VKA naïve
patients. Logistic regression analysis was used to deter-
mine variables associated with dabigatran use. Crude
incidence rates per 100 person-years and adjusted HRs
of thromboembolism and bleeding were assessed in all
patients and in previous VKA users and VKA naïve
patients.18 19 Patients were considered at risk (exposed)
from the ﬁrst date claiming a prescription of warfarin or
dabigatran during the study period between 22 August
and 31 December 2011. The study period was chosen
since the use of dabigatran was approved by 22 August
2011, and follow-up data obtained from the nationwide
registries were only available until 31 December 2011.
Patients were censored at the ﬁrst thromboembolic or
bleeding event, at death or at the end of the study
period. Adjusted risks associated with dabigatran 110
and 150 mg use were estimated using the Cox
proportional-hazards models, with warfarin as reference.
The analyses were adjusted for age-groups (<65, 65–74
and ≥75), sex, comorbidity and concomitant medical
treatment. The models were tested for the absence of
interactions, linearity of continuous variables and fulﬁl-
ment of the proportional hazard assumption, and found
to be valid. Calculations were carried out using the SAS
statistical software V.9.2 (SAS Institute, Cary, North
Carolina, USA). The study was conducted and reported
in accordance with the Strengthening and the
Reporting of Observational Studies in Epidemiology
recommendations.23
RESULTS
Prescription patterns
Between 22 August and 31 December 2011, a total of
52 366 AF patients claimed a prescription for oral antic-
oagulation. Of these, 1612 (3.1%) and 1114 (2.1%)
patients were treated with dabigatran 110 and 150 mg
twice daily, and 49 640 (94.8%) were treated with VKA.
Compared with VKA and dabigatran 110 mg twice daily,
patients treated with dabigatran 150 mg were younger
with less comorbidity, as well as lower CHA2DS2VASc and
HAS-BLED scores. Among dabigatran users, 782
(48.5%) in the 110 mg group and 349 (31.3%) in the
150 mg group had previously used VKA (p<0.001).
Baseline characteristics are presented in table 1.
Independent predictors of dabigatran use are presented
in table 2. Of note, 171 patients (34 (2.1%) and 137
(12.3%) users of dabigatran 110 and 150 mg, respect-
ively) were initiated on dabigatran without the presence
of relevant risk factors, while 481 patients only had one
‘moderate’ risk factor (122 (7.6%) and 137 (32.2%) for
dabigatran 110 and 150 mg).
Compliance with European recommendations
Among patients treated with dabigatran 110 mg, 90.3%
fulﬁlled the labelled recommendations listed by EMA;
this applied to 55.5% among users of 150 mg. Details
Table 2 Predictors associated with dabigatran use, results from the logistic regression analysis
OR 95% CI p Value
Male 1.00
Female 0.70 (0.64 to 0.76) <0.001
Age 65–74 1.14 (0.96 to 1.36) 0.14
Age ≥75 1.50 (1.24 to 1.82) <0.001
Heart failure 1.23 (1.05 to 1.44) 0.01
Hypertension 1.39 (1.13 to 1.71) 0.002
Diabetes 1.16 (1.01 to 1.32) 0.03
Previous thromboembolism 1.18 (0.97 to 1.44) 0.11
Vascular disease 1.02 (0.91 to 1.16) 0.14
Previous bleeding 1.10 (0.94 to 1.30) 0.24
CHADS2 group* 0.81 (0.70 to 0.93) 0.003
CHA2DS2–VASc group† 1.00 (0.88 to 1.14) 0.98
HAS-BLED group‡ 1.03 (0.89 to 1.19) 0.73
*CHADS2: congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischaemic attack.
†CHA2DS2–VASc: CHADS2, adding vascular disease, age 65–75 and female sex.
‡HAS-BLED: hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalised ratio (left
out due to lack of information, as carried out previously), elderly (>65 years), drugs/alcohol concomitantly.
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relating to recommended indications and contraindica-
tions are presented in table 3.
Thromboembolism and bleeding events
Duration of follow-up was 4 months and 9 days. Event
rates of thromboembolism and bleedings per 100
patient-years and number of events are shown in
ﬁgure 1 (for all patients, and in VKA experienced and
VKA naïve patients). Related adjusted HRs are shown in
ﬁgure 2.
VKA experienced versus VKA naive
VKA experienced and VKA naive patients differed in
baseline characteristics (table 4). Unexpectedly, among
all patients, the adjusted risk of thromboembolism was
higher among users of dabigatran compared with users
of warfarin, but when stratiﬁed by previous VKA use, the
increased risk of thromboembolism was only seen
among previous VKA users (for both 110 and 150 mg
doses). Among all patients, the adjusted risk of bleeding
was increased among users of dabigatran 110 mg with
warfarin as reference. Stratiﬁed by previous VKA use,
this increased risk only persisted among VKA experi-
enced patients.
DISCUSSION
This study describes the use of dabigatran and warfarin
in a nationwide cohort of AF patients after approval of
dabigatran. Our main ﬁndings were as follows: (1) dabi-
gatran was prescribed in approximately 5% of patients
with oral anticoagulation; (2) users of dabigatran
150 mg twice daily were younger with less comorbidity
Table 3 Indications and contraindication for dabigatran use
Dabigatran 110 mg Dabigatran 150 mg p Value
Indications
One risk factor
Heart failure 286 (17.7) 84 (7.5) <0.001
Previous thromboembolism 136 (8.4) 66 (5.9) 0.01
Age ≥75 years 1245 (77.2) 225 (20.2) <0.001
At least two risk factors
Hypertension 834 (51.7) 501 (44.9) <0.001
Diabetes mellitus 241 (15.0) 153 (13.7) 0.37
Vascular disease 265 (16.4) 113 (10.1) <0.001
Age 65–74 years 278 (17.3) 594 (53.3) <0.001
Risk factors
≥1 high* or ≥2 moderate* 1456 (90.3) 618 (55.5) <0.001
1 Moderate* 122 (7.6) 359 (32.2) <0.001
None 34 (2.1) 137 (12.3) <0.001
Contraindications
Liver 31 (1.9) 17 (1.5) 0.44
Kidney disease 96 (6.0) 36 (3.2) 0.001
Previous bleeding 209 (13.0) 78 (7.0) <0.001
Age ≥80 953 (59.1) 42 (3.8) <0.001
*Referring to recommendations by EMA. High risk factors: previous stroke, transient ischaemic attack, or systemic embolism, left-ventricular
ejection fraction <40%, symptomatic heart failure or age ≥75 years. Moderate risk factors: age ≥65 years, diabetes, coronary artery disease
or hypertension. A dose of 150 mg twice daily is recommended unless the patients are ≥80 years, or with increased risk of bleeding where a
dose of 110 mg twice daily is preferred/should be considered.2
Figure 1 Event rates and crude
incidence rates per 100 patient
years.
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than users of VKA and dabigatran 110 mg. A higher pro-
portion of previous VKA users was found in patients
treated with dabigatran 110 mg compared with 150 mg;
(3) European recommendations for dabigatran use were
fulﬁlled in 90.3% and 55.5% of patients with dabigatran
110 mg and 150 mg, respectively, and (4) the adjusted
risk of thromboembolism in VKA naive dabigatran users
were comparable to that in VKA (both doses of dabiga-
tran) users, but increased in previous VKA users. The
adjusted risk of bleeding was comparable to VKA in VKA
naive patients but increased among previous VKA users
prescribed dabigatran 110 mg.
Prescription patterns
Our study shows that dabigatran uptake has been rapid,
as it already constitutes 5.2% of oral anticoagulant
therapy prescribed to AF patients during the initial
4 months after approval. Slightly higher numbers have
been seen in the USA after approval, where the market
share of dabigatran was 7%, 12% and 28% during the
ﬁrst, second and ﬁfth quarters.24 In the present study,
51.5% and 68.7% of dabigatran users were VKA naive
patients (110 and 150 mg, respectively), indicating that
the novel oral anticoagulants such as dabigatran are rele-
vantly considered as ﬁrst-line oral anticoagulant
therapy.2
Compliance with European recommendations
EMA and FDA approved dabigatran use in AF patients
with at least one of the following risk factors: previous
stroke, transient ischaemic attack or systemic embolism;
left-ventricular ejection fraction <40%, symptomatic
heart failure, and age ≥75 or ≥65 years with one of the
following: diabetes, coronary artery disease or hyperten-
sion. In the USA, off-label use of dabigatran has com-
monly been shown.24 In our population, 90.3% and
55.5% of the patients treated with dabigatran 110 and
150 mg, respectively, met the EMA recommendations.2 11
Thus, off-label use with dabigatran 150 mg was also
common in our cohort.
In the present study, few patients ≥80 years were
treated with 150 mg dabigatran, compared with more
than half of the patients on 110 mg dabigatran. This is
reassurring as there is an increased risk of bleeding
among older patients; thus, 110 mg dabigatran is being
recommended in those aged >80 years.4 25 In addition,
we found that one-fourth of the patients treated with
dabigtran 150 mg had a high bleeding risk (as reﬂected
by HAS-BLED score ≥2), and some were diagnosed with
liver or renal disease. In those at high bleeding risk,
110 mg twice daily is recommended.2 26
Thromboembolism and bleedings, with or without
previous VKA use
The duration of follow-up was approximately 4 months,
since the registry data were only available for the period
until the end of 2011. In the overall cohort, we unex-
pectedly found that the adjusted risk of thromboembolic
events was increased among users of both doses of dabi-
gatran.4 Among VKA naive subjects, the risk of thrombo-
embolic events was comparable with VKA with both
doses of dabigatran, but increased in dabigatran users
who had previously used VKA. This is in contrast to
results from the RE-LY study, where thromboembolic
events among previous VKA users and VKA naive
patients were similar between groups.27 The interpret-
ation of this is that dabigatran, at least at this point, is
being used in clinical settings where VKA have failed.
Notably, these results reﬂect real-life clinical use of a
novel anticoagulant that is not necessary but is in
accordance with use in a controlled clinical trial.
Guidelines recommend a novel oral anticoagulant if war-
farin is difﬁcult to keep within therapeutic range, in
case of side-effects, or an inability to undertake inter-
national normalised ratio (INR) monitoring (class IB).2
The increased thromboembolic risk in previous VKA
users prescribed that dabigatran users can plausibly be
explained by several unmeasured confounders including
poor compliance or unmeasured serious comorbidities.
Differences in baseline characteristics between VKA
Figure 2 Adjusted risk of
thromboembolic events and
bleeding (Cox proportional hazard
model).
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naive and previous VKA users, the latter being associated
with more comorbidities, support this assumption.
Broadly comparable patterns were seen concerning
bleeding, with an increased risk among previous VKA
users treated with dabigatran 110 mg, and a similar risk
to warfarin among VKA naive patients with dabigatran.
These ﬁndings are somewhat surprising, given that VKA
naïve patients usually have more bleedings shortly after
initiation, at least in some studies18 19 27 On the other
hand, our ﬁnding supports current recommendations
that patients complying with VKA treatment who are
kept within the recommended therapeutic INR range
Table 4 Baseline differences between VKA naive and VKA experienced
Treatment group, N (%) VKA naive VKA experienced* p Value
Characteristics
Number of patients 5832 46534
Age, mean (SD), years 72.2 (±10.9) 73.8 (±9.9)
Age 65–74 years 2003 (34.3) 15669 (33.7) 0.30
Age ≥75 years 2583 (44.3) 23374 (50.2) <0.001
Female 2471 (42.4) 18168 (39.0) <0.001
Male 3361 (57.6) 28366 (60.9) <0.001
Comorbidity
Heart failure 616 (10.6) 8377 (18.0) <0.001
Hypertension 2422 (41.5) 26751 (57.5) <0.001
Diabetes mellitus 776 (13.3) 7894 (17.0) <0.001
Previous thromboembolism 351 (6.0) 3456 (7.4) <0.001
Vascular disease 809 (13.9) 6497 (14.0) 0.85
Alcohol 236 (4.1) 1598 (3.4) 0.02
Liver 94 (1.6) 644 (1.4) 0.16
Kidney disease 353 (6.0) 3120 (6.7) 0.06
Previous bleeding 492 (8.4) 4966 (10.7) <0.001
Warfarin 4237 (72.7) 45403 (97.6) <0.001
Dabigatran 110 mg 830 (14.2) 782 (1.7) <0.001
Dabigatran 150 mg 765 (13.1) 349 (0.8) <0.001
Concomitant therapy
Digoxin 808 (13.9) 16934 (36.4) <0.001
Amiodarone 158 (2.7) 2244 (4.8) <0.001
Class 1C AA† 88 (1.5) 941 (2.0) 0.008
Sotalol 118 (2.0) 902 (1.9) 0.66
β-Blockers 2499 (42.9) 29996 (64.5) <0.001
Non-dihydropyridine CCBs‡ 1604 (27.5) 14436 (31.0) <0.001
NSAIDs 1172 (20.1) 6929 (14.9) <0.001
Aspirin 2517 (43.2) 13429 (28.9) <0.001
CHADS2§
Low (score 0) 1713 (29.4) 7610 (16.4) <0.001
Intermediate (score 1) 2081 (35.7) 15971 (34.3) <0.001
High (score 2–6) 2038 (35.0) 22953 (49.3) <0.001
Mean score (SD) 1.2 (±1.1) 1.6 (±1.1)
CHA2DS2-VASc¶
Low (score 0) 500 (8.6) 1849 (4.0) <0.001
Intermediate (score 1) 991 (17.0) 5758 (12.4) <0.001
High (score 2–6) 4341 (74.4) 38927 (83.7) <0.001
Mean score (SD) 2.6 (±1.5) 2.9 (±1.5)
HAS-BLED**
Low (score 0) 1997 (34.2) 13784 (29.6) <0.001
Intermediate (score 1) 1994 (34.1) 17619 (37.9) <0.001
High (score 2–6) 1841 (31.6) 15131 (32.5) <0.001
Mean score (SD) 2.0 (±1.1) 2.1 (±1.0)
*Previous VKA use/VKA experienced: Prescription claims of warfarin from 0 to 180 days prior to baseline stratification.
†Class 1C AA:drug coded as ATC ‘C01B’.
‡Non-dihydropyridine CCBs: drugs coded as ‘C08DA’.
§CHADS2: Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, Stroke/transient ischaemic attack.
¶CHA2DS2–VASc: CHADS2, adding vascular disease, age 65–75 and female sex.
**HAS-BLED: hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalised ratio(left
out due to lack of information, as carried out previously), elderly (>65 years), drugs/alcohol concomitantly.
NSAIDs, non-steroidal anti-inflammatory drugs; VKA, vitamin K antagonist.
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(ie, with high time in therapeutic range) should remain
on warfarin treatment rather than ‘switch’. As patients
treated with dabigatran 110 mg twice daily in our study
were older, with more comobidity and a higher
HAS-BLED score (with increased bleeding risk), this
could be a product of unmeasured confounders.25
Patients treated with dabigatran 110 mg twice daily had
higher CHA2DS2-VASc and HAS-BLED scores than
patients treated with dabigatran 150 mg twice daily, as
did previous VKA users compared with VKA naive
patients. One previous study showed that patients with
both high CHA2DS2-VASc and HAS-BLED scores had
the most net-clinical beneﬁt from VKA treatment.22
Whether the high-risk patients in our study would have
shown a net-clinical beneﬁt from 150 mg twice daily
instead of 110 mg dabigatran cannot be concluded from
the present analyses. However, it is possible that clini-
cians may have opted to particularly use dabigatran
110 mg twice daily in patients perceived to be at high
risk for bleeding (ie, high HAS-BLED score) as the
primary consideration, and given that stroke and bleed-
ing risk parallel each other, the CHA2DS2-VASc score
was correspondingly higher.
With cautious interpretation due to the low number of
events and short follow-up, dabigatran use in VKA naive
patients seems to be a safe option in our study without
an increased risk of thromboembolic or bleeding
events.27 In addition, our results call for a more cautious
approach when shifting high-risk patients from VKA to
dabigatran treatment.
Strengths and limitations
The strength of this study is the completeness of data,
with a nationwide unselected cohort of AF patients
initiated on oral anticoagulation. In Denmark, all citizens
regardless of socioeconomic status, healthcare-insurance
and geography are covered by a public healthcare system
ensuring complete registration of outpatient contacts
and hospital admissions. The pharmacies also register all
claimed prescriptions. By the use of a unique personal
registration number, administrative registers can be
linked on an individual level. In this setting, it is possible
to describe the initial Danish experience with dabigatran,
compared with VKA, and indirectly reveal the doctors’
interpretation of EMA’s recommendations for dabigatran
use in clinical practice. The register data used have been
validated previously,16 17 28–30 as have the methods used
for assessment of comorbidity and risk stratiﬁcation in
patients with AF.18 20–22
One limitation is that we had no information of INR
values, time in therapeutic range or creatine clearance.
To overcome this drawback, methods from previous
studies were used.22 In the adjusted analyses, we
included known confounders present in our registries,
but unmeasured confounders may still have inﬂuenced
our results. Another major limitation is the short period
of follow-up, and thus the low number of events of both
thromboembolism and bleeding. Thus, interpretations
of these risks should be cautious and seen in the context
of an early pattern after approval of dabigatran. In add-
ition, our deﬁnition of bleeding varies from the deﬁn-
ition used in the RE-LY trial,4 but at least it includes
serious bleedings leading to hospitalisation, as has been
used previously.18
CONCLUSION
Deviations from the recommended use of dabigatran
were frequent among patients treated with 150 mg twice
daily. Dabigatran use in VKA naive patients with AF
seems safe. Reasons for the increased risk of thrombo-
embolic events with dabigatran (and bleeding with
110 mg twice daily) among previous VKA users may
reﬂect patient selection and ‘drug switching’ practices
that merit a more cautious approach when shifting high-
risk patients from VKA to dabigatran treatment.
Additional real-life follow-up data of dabigatran use are
warranted in the future.
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